HCV clearance from saliva of HIV–HCV-coinfected patients on treatment with interferon plus ribavirin
Article first published online: 22 APR 2013
© 2013 John Wiley & Sons A/S
Volume 20, Issue 3, pages 313–318, April 2014
How to Cite
Oral Diseases (2014) 20, 313–318
- Issue published online: 14 MAR 2014
- Article first published online: 22 APR 2013
- Accepted manuscript online: 12 APR 2013 02:44AM EST
- Manuscript Accepted: 4 APR 2013
- Manuscript Revised: 27 MAR 2013
- Manuscript Received: 12 FEB 2013
- hepatitis C virus;
- human immunodeficiency virus;
To determine hepatitis C virus (HCV) RNA clearance from blood and saliva of HIV–HCV-coinfected patients undergoing combined therapy with pegylated interferon plus ribavirin (PEG-IFN-RIB).
Subjects and Methods
Study group was formed of 60 HIV-infected patients with chronic hepatitis C who were starting treatment with PEG-IFN-RIB. Blood and saliva samples were taken at baseline, at the end of treatment and 24 and 48 weeks later. A nested RT-PCR technique was used to detect HCV-RNA in saliva.
HCV-RNA was detected in saliva at baseline in 64.7% of patients. Thirty-four patients completed follow-up. The response rate (undetectable HCV-RNA) in blood was 79.4% at the end of treatment; 55.8% at 24 weeks after the end of treatment and 50% at 48 weeks. HCV was detected in saliva of 13 (38.2%) patients at the end of treatment and in 18 (52.9%) patients at 24 and 48 weeks later. Concordance of HCV clearance from blood and saliva reached its maximum value at 48 weeks after the end of treatment (odds ratio, 112.51).
In HIV–HCV-coinfected patients responders to PEG-IFN-RIB, the salivary glands do not appear to be a sanctuary site for HCV, although viral clearance from saliva may be slower than from blood.